Home » Stocks » Odonate Therapeutics

Odonate Therapeutics, Inc. (ODT)

Stock Price: $15.52 USD -0.17 (-1.08%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 498.61M
Revenue (ttm) n/a
Net Income (ttm) -118.07M
Shares Out 32.13M
EPS (ttm) -3.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $15.52
Previous Close $15.69
Change ($) -0.17
Change (%) -1.08%
Day's Open 15.60
Day's Range 15.33 - 15.90
Day's Volume 371,475
52-Week Range 12.56 - 46.50

More Stats

Market Cap 498.61M
Enterprise Value 374.39M
Earnings Date (est) Feb 19, 2021
Ex-Dividend Date n/a
Shares Outstanding 32.13M
Float 29.73M
EPS (basic) -3.86
EPS (diluted) -3.86
FCF / Share -3.36
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.31M
Short Ratio 5.58
Short % of Float 7.76%
Beta 0.65
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.04
Revenue n/a
Operating Income -120.82M
Net Income -118.07M
Free Cash Flow -103.07M
Net Cash 124.22M
Net Cash / Share 3.87
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -43.48%
ROE -79.66%
ROIC 771.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

$35.00*
(125.52% upside)
Low
10.0
Current: $15.52
High
50.0
Target: 35.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue-----
Operating Income-115-90.76-32.74-3.09-0.16
Net Income-112-88.96-32.74-3.09-0.16
Shares Outstanding27.6324.4614.175.760.92
Earnings Per Share-4.05-3.64-2.31-0.54-0.17
Operating Cash Flow-96.64-67.09-25.86-1.73-0.17
Capital Expenditures-0.17-1.91-0.08--
Free Cash Flow-96.80-69.00-25.94-1.73-0.17
Cash & Equivalents1811391982.600.14
Total Debt2.06----
Net Cash / Debt1791391982.600.14
Assets1891432032.880.14
Liabilities26.5318.677.510.600.03
Book Value1621241962.280.11
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Odonate Therapeutics, Inc.
Country United States
Employees 134
CEO Kevin C. Tang

Stock Information

Ticker Symbol ODT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ODT
IPO Date December 7, 2017

Description

Odonate Therapeutics, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer; and CONTESSA 2 and CONTESSA TRIO, which is in Phase II clinical study for central nervous system metastases and various cancer treatments. The company was founded in 2013 and is based in San Diego, California.